Under terms of the Letter of Intent signed between the organizations, Biostar will coordinate with FMMU to complete clinical trials before October 2015, and will fund and carry out trials and approvals, as well as complete the construction of a production line, obtain GMP certification, and manufacture the drug using FMMU technology. FMMU will submit applications relating to the start of trials, coordinate with China’s military authorities, and secure final product approvals.

The LOI follows a cooperation agreement signed in January 2012 under which Biostar was sleected to share resources and ideas with FMMU, and to collaborate on the clinical trials of products in development for China’s military, and hospitals managed by FMMU. “Following the initial clinical research, Viacom has demonstrated encouraging results for the treatment of several skin diseases such as bacterial and fungal infections, dermatitis, and eczema, which are common among members of the People’s Republic of China armed forces,” explains Ronghua Want, Biostar chairman and CEO. “Once Viacom receives approval from the military authorities to be sold in military hospitals, we will apply to receive the State Food & Drug Administration’s approval to sell it in healthcare centers and hospitals all over the country.”

Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.

If you have any questions about your subscription, click
hereto email us or call at (914) 740-2189.

You may also be interested in subscribing to the GEN magazine, an indispensable
resource for everyone involved in the business of translating discoveries at the
bench into solutions that fight disease and improve health, agriculture, and the
environment. Subscribe
today to see why over 60,000 biotech professionals read GEN to
keep current in the areas of genomics, proteomics, drug discovery, biomarker discovery,
bioprocessing, molecular diagnostics, collaborations, biotech business trends, and
more.